Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic

In vivo biomarker abnormalities provide measures to monitor therapeutic interventions targeting amyloid-β pathology as well as its effects on downstream processes associated with Alzheimer’s disease pathophysiology. Here, we applied an in vivo longitudinal study design combined with imaging and cere...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Min Su, Shin, Monica, Ottoy, Julie, Aliaga, Arturo Aliaga, Mathotaarachchi, Sulantha, Quispialaya, Kely, Pascoal, Tharick A, Collins, D Louis, Chakravarty, M. Mallar, Mathieu, Axel, Sandelius, Åsa, Blennow, Kaj, Zetterberg, Henrik, Massarweh, Gassan, Soucy, Jean-Paul, Cuello, A Claudio, Gauthier, Serge, Waterston, Michael, Yoganathan, Nathan, Lessard, Etienne, Haqqani, Arsalan, Rennie, Kerry, Stanimirovic, Danica, Chakravarthy, Balu, Rosa-Neto, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014686/
https://www.ncbi.nlm.nih.gov/pubmed/34378436
http://dx.doi.org/10.1177/0271678X211035625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014686/
https://www.ncbi.nlm.nih.gov/pubmed/34378436
http://dx.doi.org/10.1177/0271678X211035625

Ejemplares similares